BACKGROUND: Psoriasis is an inflammatory disease of the skin and joints. Previous studies have shown a higher prevalence of metabolic syndrome (MS) in psoriatic patients. Recent studies show that non-alcoholic fatty liver disease (NAFLD) is also frequent in psoriasis patients. OBJECTIVES: To investigate the occurrence and severity of NAFLD in South Indian psoriatic patients and healthy controls. METHODS: In phase 1 we performed a case control study on 333 adult psoriasis patients and 330 controls matched by age, sex and body mass index. NAFLD was diagnosed by ultrasonography and liver enzymes after excluding other liver diseases. In phase 2 we compared the NAFLD subgroups in psoriasis patients and controls by determining their fibrosis, steatosis and non-alcoholic steatohepatitis (NASH) scores. RESULTS: The occurrence of NAFLD was higher in psoriasis patients than in controls (17.4 vs 7.9%; P = 0.002). NAFLD patients in the psoriasis group (n = 58) were more likely to have MS (P = 0.03) and diabetes (P = 0.02) than those with psoriasis alone (n = 254). The former group had a longer duration of psoriasis and arthritis (P = 0.003 and 0.005). Psoriasis patients with NAFLD had more severe disease as per the psoriasis area and severity index scores (P = 0.02). Psoriasis patients had more severe NAFLD than controls as reflected by the steatosis, NASH and fibrosis scores (P = 0.001, 0.003, 0.03 respectively). CONCLUSION: NAFLD is the commonest liver disease in Indian psoriatic patients when compared to controls. As NAFLD is more severe in psoriasis patients we suggest routine screening for NAFLD in this group especially when systemic therapy is considered.
BACKGROUND:Psoriasis is an inflammatory disease of the skin and joints. Previous studies have shown a higher prevalence of metabolic syndrome (MS) in psoriaticpatients. Recent studies show that non-alcoholic fatty liver disease (NAFLD) is also frequent in psoriasispatients. OBJECTIVES: To investigate the occurrence and severity of NAFLD in South Indian psoriaticpatients and healthy controls. METHODS: In phase 1 we performed a case control study on 333 adult psoriasispatients and 330 controls matched by age, sex and body mass index. NAFLD was diagnosed by ultrasonography and liver enzymes after excluding other liver diseases. In phase 2 we compared the NAFLD subgroups in psoriasispatients and controls by determining their fibrosis, steatosis and non-alcoholic steatohepatitis (NASH) scores. RESULTS: The occurrence of NAFLD was higher in psoriasispatients than in controls (17.4 vs 7.9%; P = 0.002). NAFLD patients in the psoriasis group (n = 58) were more likely to have MS (P = 0.03) and diabetes (P = 0.02) than those with psoriasis alone (n = 254). The former group had a longer duration of psoriasis and arthritis (P = 0.003 and 0.005). Psoriasispatients with NAFLD had more severe disease as per the psoriasis area and severity index scores (P = 0.02). Psoriasispatients had more severe NAFLD than controls as reflected by the steatosis, NASH and fibrosis scores (P = 0.001, 0.003, 0.03 respectively). CONCLUSION: NAFLD is the commonest liver disease in Indian psoriaticpatients when compared to controls. As NAFLD is more severe in psoriasispatients we suggest routine screening for NAFLD in this group especially when systemic therapy is considered.
Authors: Alexis Ogdie; Sungat K Grewal; Megan H Noe; Daniel B Shin; Junko Takeshita; Zelma C Chiesa Fuxench; Rotonya M Carr; Joel M Gelfand Journal: J Invest Dermatol Date: 2017-11-02 Impact factor: 8.551
Authors: Maria de Fátima Santos Paim de Oliveira; Bruno de Oliveira Rocha; Gleison Vieira Duarte Journal: An Bras Dermatol Date: 2015 Jan-Feb Impact factor: 1.896
Authors: A B Kimball; C Leonardi; M Stahle; W Gulliver; M Chevrier; S Fakharzadeh; K Goyal; S Calabro; W Langholff; A Menter Journal: Br J Dermatol Date: 2014-07-16 Impact factor: 9.302